Colorado man first in state to receive pioneering pancreatic cancer drug
A Lafayette father with stage 4 pancreatic cancer is the first patient in Colorado to receive Zenocutuzumab, a newly FDA-approved targeted therapy that targets the tumor's NRG1 gene fusion after chemotherapy stopped working; since starting the drug, he has shown a dramatic response and improved quality of life, illustrating a broader shift toward precision medicine in pancreatic cancer that could extend survival for some patients.